PURPOSE: In the Anastrozole, Tamoxifen Alone or in Combination trial, the combination arm was inferior to anastrozole alone in terms of disease-free survival possibly due to an adverse pharmacokinetic interaction or a predominant estrogenic effect of tamoxifen under estrogen deprivation. We assessed whether the addition of a lower dose of tamoxifen influenced anastrozole bioavailability and favorably modulated biomarkers of bone fracture, breast cancer, cardiovascular disease, and endometrial cancer risk. The influence of CYP2D6 genotype on tamoxifen effects was also determined. EXPERIMENTAL DESIGN:Seventy-five postmenopausal women with breast intraepithelial neoplasia were randomly allocated to either 1 mg/d anastrozole or 10 mg/wk tamoxifen or their combination for 12 months. Study endpoints were plasma drug concentrations and changes of C-telopeptide, osteocalcin, estradiol/sex hormone binding globulin (SHBG) ratio, estrone sulfate, insulin-like growth factor-I (IGF-I)/insulin-like growth factor binding protein-3 (IGFBP-3), C-reactive protein, antithrombin-III, endometrial Ki-67 expression, and thickness. RESULTS:Anastrozole concentrations were not affected by the combination with low-dose tamoxifen, whereas endoxifen levels were lower in poor CYP2D6 metabolizers. C-telopeptide increased by 20% with anastrozole and decreased by 16% with tamoxifen and by 7% with their combination (P < 0.001); osteocalcin showed similar changes. Compared with anastrozole, the combination arm showed lower IGF-I/IGFBP-3 levels (-17% versus -9%; P = 0.004) and lower estradiol/SHBG and estrone sulfate reductions (-15% versus -29% and -30% versus 38%, respectively). However, IGF-I/IGFBP-3 and estradiol/SHBG did not decrease in poor CYP2D6 metabolizers. Endometrial thickness was not greater in the combination than in the anastrozole arm. CONCLUSIONS: The addition of a weekly tamoxifen administration did not impair anastrozole bioavailability and modulated favorably its safety profile, providing the rationale for further studies.
RCT Entities:
PURPOSE: In the Anastrozole, Tamoxifen Alone or in Combination trial, the combination arm was inferior to anastrozole alone in terms of disease-free survival possibly due to an adverse pharmacokinetic interaction or a predominant estrogenic effect of tamoxifen under estrogen deprivation. We assessed whether the addition of a lower dose of tamoxifen influenced anastrozole bioavailability and favorably modulated biomarkers of bone fracture, breast cancer, cardiovascular disease, and endometrial cancer risk. The influence of CYP2D6 genotype on tamoxifen effects was also determined. EXPERIMENTAL DESIGN: Seventy-five postmenopausal women with breast intraepithelial neoplasia were randomly allocated to either 1 mg/d anastrozole or 10 mg/wk tamoxifen or their combination for 12 months. Study endpoints were plasma drug concentrations and changes of C-telopeptide, osteocalcin, estradiol/sex hormone binding globulin (SHBG) ratio, estrone sulfate, insulin-like growth factor-I (IGF-I)/insulin-like growth factor binding protein-3 (IGFBP-3), C-reactive protein, antithrombin-III, endometrial Ki-67 expression, and thickness. RESULTS:Anastrozole concentrations were not affected by the combination with low-dose tamoxifen, whereas endoxifen levels were lower in poor CYP2D6 metabolizers. C-telopeptide increased by 20% with anastrozole and decreased by 16% with tamoxifen and by 7% with their combination (P < 0.001); osteocalcin showed similar changes. Compared with anastrozole, the combination arm showed lower IGF-I/IGFBP-3 levels (-17% versus -9%; P = 0.004) and lower estradiol/SHBG and estrone sulfate reductions (-15% versus -29% and -30% versus 38%, respectively). However, IGF-I/IGFBP-3 and estradiol/SHBG did not decrease in poor CYP2D6 metabolizers. Endometrial thickness was not greater in the combination than in the anastrozole arm. CONCLUSIONS: The addition of a weekly tamoxifen administration did not impair anastrozole bioavailability and modulated favorably its safety profile, providing the rationale for further studies.
Authors: Catherine Duggan; Ching-Yun Wang; Marian L Neuhouser; Liren Xiao; Ashley Wilder Smith; Kerryn W Reding; Richard N Baumgartner; Kathy B Baumgartner; Leslie Bernstein; Rachel Ballard-Barbash; Anne McTiernan Journal: Int J Cancer Date: 2012-09-01 Impact factor: 7.396
Authors: Thomas Helland; Jennifer Gjerde; Simon Dankel; Ingvild S Fenne; Linn Skartveit; Andreas Drangevåg; Olivera Bozickovic; Marianne Hauglid Flågeng; Håvard Søiland; Gunnar Mellgren; Ernst A Lien Journal: PLoS One Date: 2015-04-13 Impact factor: 3.240
Authors: Matteo Lazzeroni; Davide Serrano; Barbara K Dunn; Brandy M Heckman-Stoddard; Oukseub Lee; Seema Khan; Andrea Decensi Journal: Breast Cancer Res Date: 2012-10-29 Impact factor: 6.466
Authors: Davide Serrano; Matteo Lazzeroni; Sara Gandini; Debora Macis; Harriet Johansson; Jennifer Gjerde; Ernst Lien; Irene Feroce; Giancarlo Pruneri; Maria Sandri; Fabio Bassi; Fabricio Brenelli; Alberto Luini; Massimiliano Cazzaniga; Clara Varricchio; Aliana Guerrieri-Gonzaga; Andrea DeCensi; Bernardo Bonanni Journal: Breast Cancer Res Date: 2013-06-20 Impact factor: 6.466
Authors: Aliana Guerrieri-Gonzaga; Davide Serrano; Parjhitham Thomas; Katherine D Crew; Nagi B Kumar; Sara Gandini; Lana A Vornik; Jack Lee; Sara Cagnacci; Elisa Vicini; Chiara A Accornero; Mauro D'Amico; Flavio Guasone; Stefano Spinaci; Tania B Webber; Powel H Brown; Eva Szabo; Brandy Heckman-Stoddard; Bernardo Bonanni Journal: Contemp Clin Trials Date: 2021-07-01 Impact factor: 2.226